TARA Protara Therapeutics, Inc.
$3.82▲ +0.79%
Healthcare
Other
After hours
$3.82▲ +0.00%
Sep 11, 7:30 PM ET
Volume 532.0K
Avg Volume (10D) 330.3K
Key Metrics & Fundamentals
Market Cap
$225.74M
P/E Ratio
–
Div Yield
–%
52W Range
3.02 - 7.82
% vs 50 MA
-5.28%
% vs 200 MA
-25.58%
RSI-14
40.3
MACD Histogram
+0.0000
Beta (1Y vs SPY)
1.05
Free Cash Flow
-$15.72M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$23.26M
COGS
–
Operating Exp
$23.32M
Operating Income
-$23.32M
EBIT
-$23.32M
Pretax Income
-$21.67M
Net Income
-$21.67M
EPS (Diluted)
-0.36
Price & Volume History
Loading chart…
Recent News
Protara Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
GlobeNewswire · Sep 8, 2026 8:05 PM
Protara Therapeutics: Q2 Earnings Snapshot
Associated Press · Aug 11, 2026 12:11 PM
Protara Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update
GlobeNewswire · Aug 11, 2026 12:00 PM
What Makes Protara Therapeutics (TARA) a New Buy Stock
Zacks · Jul 21, 2026 4:00 PM
Protara Therapeutics CMO Leonardo Viana Nicacio Resigns
MT Newswires · Jun 30, 2026 11:30 AM
Non-muscle Invasive Bladder Cancer Market Dynamics to Shift During the Forecast Period (2026-2036) as Novel Targeted and Gene Therapies Enter Late-Stage Development | DelveInsight
PR Newswire · Jun 23, 2026 2:31 PM
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See TARA's money flow as a full page
Social Sentiment
Avg +0.70 · 2 posts
PriceTargetNewsProtara therapeutic
r/StockMarket · Dec 5, 2024
The post highlights positive analyst forecasts and a 'Strong Buy' rating, indicating optimism.
positive
+0.60
DDPriceTarget$TARA is one of the most undervalued
r/wallstreetbets · Sep 16, 2024
The author expresses a bullish view, highlighting undervaluation and potential revenue growth.
positive
+0.80
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.